CLOs on the Move

Calithera

www.calithera.com

 
Calithera is discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Tumor metabolism and tumor immunology have emerged as promising new fields for cancer drug discovery, and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients. Our lead product candidate in tumor metabolism, CB-839, is an internally discovered, ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.calithera.com
  • 343 Oyster Point Blvd Suite 200
    South San Francisco, CA USA 94080
  • Phone: 650.870.1000

Executives

Name Title Contact Details
Sumita Ray
General Counsel Profile

Similar Companies

Amisure International

Amisure International is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BreakBio

BreakBio Corp is a biotechnology company focused on breakthrough cancer treatment and prevention. They use their proprietary AI platform to find multiple proteins on each patients cancer cells and custom manufacture drugs for each patient. Their goal ...

MYM Nutraceuticals

MYM Nutraceuticals Inc. (CSC:MYM) (OTC:MYMMF) (FRA:OMY) is an emerging bio-pharmaceutical company and distributor of medical marijuana products that has applied to Health Canada for a medical marijuana production and distribution license under the Marihuana for Medical Purposes Regulations. MYM Nutraceuticals has an extensive list of industry assets that make it well prepared for commercial distribution of medical marijuana, including a growing facility property, exclusive access to patients and many years of industry expertise on the company`s board of directors and staff.

Impact Biomedicines

Impact Biomedicines, Inc. (Impact) is pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. Led by a highly skilled and devoted team, Impact is advancing a late-stage pipeline centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor, which is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Impact was formed in 2016 after acquisition of Sanofi’s full rights for the global development and commercialization of fedratinib. The Impact team intends to pursue multiple clinical indications for fedratinib to maximize its potential as a best-in-class therapy for JAK2-dependent diseases.

Synthego

Synthego is a leading provider of genome engineering solutions. Our flagship product, CRISPRevolution, is a portfolio of synthetic guide RNA designed for CRISPR genome editing and research. Synthego`s vision is to bring precision and automation to genome engineering, enabling rapid and cost-effective research with consistent results for every scientist.